Ethic Inc. Sells 15,402 Shares of Zoetis Inc. $ZTS

Ethic Inc. decreased its position in Zoetis Inc. (NYSE:ZTS) by 28.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 37,851 shares of the company’s stock after selling 15,402 shares during the quarter. Ethic Inc.’s holdings in Zoetis were worth $5,538,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Scott & Selber Inc. grew its stake in Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after buying an additional 67 shares during the last quarter. North Star Asset Management Inc. grew its position in Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after acquiring an additional 67 shares during the last quarter. Secure Asset Management LLC grew its position in Zoetis by 2.9% during the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after acquiring an additional 68 shares during the last quarter. Moment Partners LLC increased its holdings in Zoetis by 3.2% during the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after purchasing an additional 72 shares in the last quarter. Finally, CVA Family Office LLC raised its position in Zoetis by 6.7% in the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after purchasing an additional 74 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 0.3%

NYSE ZTS opened at $125.90 on Tuesday. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.40. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The firm has a market cap of $55.48 billion, a P/E ratio of 21.19, a P/E/G ratio of 2.74 and a beta of 0.97. The stock’s 50-day moving average is $126.66 and its 200-day moving average is $142.51.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the company posted $1.58 EPS. The business’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. This is a boost from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Analyst Ratings Changes

ZTS has been the topic of several research analyst reports. Barclays initiated coverage on Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. HSBC set a $140.00 target price on shares of Zoetis in a research note on Wednesday, December 10th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Finally, Morgan Stanley set a $160.00 price objective on shares of Zoetis in a research report on Thursday, December 18th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.